Tempus HRD-RNA is an AI-driven, 1,660-gene logistic regression model designed to identify patients likely to respond to ...

Tempus AI, Inc. (NASDAQ:TEM) shares are climbing today after the company unveiled a new AI-powered cancer diagnostic ...

Tempus AI launched its HRD-RNA algorithm, an AI-driven model for identifying Homologous Recombination Deficiency in cancer patients. The company also partnered with Median Technologies to integrate ...

Tempus AI Inc. TEM shares are up on Thursday as Mizuho initiated coverage on the health care-focused artificial intelligence firm. Analyst Bradley Bowers started coverage with an Outperform rating and ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA ...

Tempus AI TEM rose on Wednesday after the company unveiled its new HRD-RNA algorithm, an AI-driven tool designed to improve ...

Investing.com -- Tempus AI, Inc. (NASDAQ:TEM) stock rose 3.5% Wednesday after the precision medicine technology company announced the launch of its new HRD-RNA algorithm for cancer detection.

A machine learning algorithm used gene expression profiles of patients with gout to predict flares. The PyTorch neural network performed best, with an area under the curve of 65%. The PyTorch model ...